Aeglea Bio Therapeutics Inc
Change company Symbol lookup
Select an option...
AGLE Aeglea Bio Therapeutics Inc
GME GameStop Corp
XELA Exela Technologies Inc
ARKK ARK Innovation ETF
NVVEW Nuvve Holding Equity Warrants Exp 19 March 2026 *W EXP 03/19/2026
BEPH Brookfield BRP Holdings (Canada) Inc
CHKP Check Point Software Technologies Ltd
FDX FedEx Corp
VLON Vallon Pharmaceuticals Inc
HCNEU Jaws Hurricane Acquisition Corp
Go

Health Care : Biotechnology |
Company profile

Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing human enzyme therapeutics to benefit people with rare metabolic diseases. The Company’s product candidates include pegzilarginase and AGLE-177. The Company's lead product candidate, pegzilarginase, is a recombinant human arginase one that enzymatically degrades the amino acid arginine to lower arginine levels in patients with Arginase one Deficiency. Its engineered pegzilarginase with modifications that enhance the stability and arginine-degrading activity of the enzyme in human plasma. The Company is evaluating Pegzilarginase in a global pivotal Phase III PEACE (Pegzilarginase Effect on Arginase one Deficiency Clinical Endpoints) trial and in a Phase II open-label extension study for patients with Arginase One Deficiency. Its AGLE-177, is a novel PEGylated, or polyethylene glycol modified, human enzyme engineered to reduce Homocystinuria.

Closing Price
$6.00
Day's Change
-0.17 (-2.76%)
Bid
--
Ask
--
B/A Size
--
Day's High
6.21
Day's Low
5.90
Volume
(Average)
Volume:
157,454

10-day average volume:
174,612
157,454

'Electric profits': Wall Street analysts race to lift Tesla price targets with Wedbush sitting at $1,100 a share

9:59 am ET October 23, 2021 (MarketWatch)
Print

By Barbara Kollmeyer and Claudia Assis

A dozen analysts raised price targets after Wednesday's results

Not even supply-chain worries can get a Tesla bull down, with Wall Street analysts racing Thursday to upgrade their price targets following the electric car maker's third-quarter results, which sent Tesla shares rallying.

Late Wednesday, the EV giant reported record third-quarter profit -- $1.6 billion, or $1.44 a share -- and sales -- up 57% to $13.8 billion -- but also cut language in its outlook that had kept it optimistic about 2021's growth. In a refrain heard across many industries right now, Tesla complained of clogged ports and other supply-chain problems preventing its factories from running at maximum capacity.

Read:Tesla hits record quarterly profit, says supply-chain snags kept its factories from running 'full speed'

Tesla's hesitation resulted in some premarket selling, with shares down 1.3%, but by midday trading Thursday the stock was up nearly 4% and on pace to end at a record high. The stock traded as high as $899.00, its highest intraday level since Jan. 25, when it hit $900.40.

No less than a dozen analysts raised their price targets as of Thursday, according to FactSet.

Among those enthuistically greeting those results were Wedbush analysts Dan Ives and John Katsingris, who boosted their 12-month Tesla target to $1,100 a share from $1,000, maintaining an outperform rating. They see Tesla at the head of a "green tidal wave" that they expect will kick into gear in 2022.

Wedbush isn't even the biggest bull on Wall Street, which goes to Elazar Advisors' Chaim Siegel, who has a 12-month target of $1,591. Of the 41 analysts FactSet covers, eight have price targets of $1,000 or higher.

As for the supply-chain issues, the pair said that likely took around 40,000 cars off Tesla's annual numbers, but see the company still producing around 900,000 for 2021 "with a 1.3 million/1.4 million bogey for 2022." Wedbush's long-term bull case now stands at $1,500 a share, up from $1,300 previously.

Pulling out more positives, Ives and Katsingris said the company's adjusted EBITDA, or earnings before interest, taxes, depreciation, and amortization of $3.2 billion solidly beat the Street's $2.79 billion estimate. That speaks to a "more profitable Tesla going forward which is key to a higher rerating on the stock," he said.

Describing Tesla's (TSLA) record quarterly profit and sales as "electric," Baird analysts Ben Kallo and George Gianarikas boosted their own price target to $888 a share.

"Tesla reported exceptional profitability as it continues to flex its operational chops by outperforming its industry peers in delivering strong volumes in an environment marred by supply-chain issues while improving profits to an all-time record," said the pair in a note.

Opinion: Tesla's earnings show is more cautious -- and yes, boring -- without Elon around

"After delivering another impressive quarter of cost leverage and posting EBIT margin above longer term 'low-teen' guidance, Tesla is reaching a juncture where it can better control balancing pricing, margin and affordability, especially if approaching a tipping point where software becomes a bigger contributor to the business model," said a team of Jefferies analysts led by Philippe Houchois, who rate Tesla a buy with a price target of $950 per share.

Mizuho analysts Vijay Rakesh and Jason Gez lifted their Tesla price target to $950 per share from $825. Reiterating their buy rating, they said Tesla and rival NIO are "well positioned," with secular growth in EV driving around 30% compound annual growth rate [CAGR] between 2020 and 2030, and Tesla noting its own 50% CAGR production target.

The post-results call without Chief Executive Elon Musk, who said in July he'd only be on the calls if Tesla a major announcement, was "less eventful," RBC Securities Joseph Spak said in his note.

Spak raised his price target on Tesla shares to $800 due to "confidence in (Tesla's) long-term trajectory," but said near-term pressures include rising commodity costs and logistics costs and impact of labor shortages.

Bernstein analyst Toni Sacconaghi remained a Tesla bear, however, saying he continues "to struggle to justify (Tesla's) valuation, which is higher than all other major auto makers combined and appears to imply huge volume AND industry leading profitability going forward, which is historically unprecedented."

Sacconaghi rates the stock the equivalent of sell with a price target of $300, which implies a 65% downside over Thursday's prices.

Even his bearish stance, however, didn't prevent him from saying that Tesla "appears to have done an exemplary job managing through supply chain challenges in the quarter."

-Barbara Kollmeyer

	

(END) Dow Jones Newswires

October 23, 2021 09:59 ET (13:59 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.